Geode Capital Management
VRTX icon

Geode Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Geode Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.73B Buy
6,139,621
+157,716
+3% +$73.5M 0.17% 95
2025
Q4 		$2.7B Buy
5,981,905
+8,160
+0.1% +$3.52M 0.17% 95
2025
Q3 		$2.33B Buy
5,973,745
+44,998
+0.8% +$18.8M 0.15% 111
2025
Q2 		$2.63B Buy
5,928,747
+166,987
+3% +$77M 0.18% 93
2025
Q1 		$2.78B Buy
5,761,760
+113,524
+2% +$52.9M 0.22% 82
2024
Q4 		$2.27B Sell
5,648,236
-287,652
-5% -$133M 0.18% 90
2024
Q3 		$2.75B Sell
5,935,888
-389,420
-6% -$187M 0.22% 71
2024
Q2 		$2.96B Buy
6,325,308
+512,272
+9% +$222M 0.26% 61
2024
Q1 		$2.42B Buy
5,813,036
+139,617
+2% +$59M 0.22% 76
2023
Q4 		$2.3B Buy
5,673,419
+77,445
+1% +$28.6M 0.24% 71
2023
Q3 		$1.94B Buy
5,595,974
+51,113
+0.9% +$17.9M 0.23% 75
2023
Q2 		$1.95B Buy
5,544,861
+135,604
+3% +$45.7M 0.23% 78
2023
Q1 		$1.7B Buy
5,409,257
+26,538
+0.5% +$7.96M 0.22% 87
2022
Q4 		$1.55B Buy
5,382,719
+111,052
+2% +$33.8M 0.22% 90
2022
Q3 		$1.52B Buy
5,271,667
+737,183
+16% +$212M 0.23% 78
2022
Q2 		$1.28B Buy
4,534,484
+204,253
+5% +$54.7M 0.19% 97
2022
Q1 		$1.13B Sell
4,330,231
-25,989
-0.6% -$6.17M 0.14% 123
2021
Q4 		$954M Buy
4,356,220
+53,868
+1% +$10.5M 0.11% 154
2021
Q3 		$778M Buy
4,302,352
+215,173
+5% +$42M 0.1% 172
2021
Q2 		$822M Buy
4,087,179
+145,993
+4% +$30.5M 0.11% 155
2021
Q1 		$845M Buy
3,941,186
+54,343
+1% +$11.9M 0.13% 136
2020
Q4 		$916M Buy
3,886,843
+12,691
+0.3% +$2.91M 0.15% 119
2020
Q3 		$1.05B Buy
3,874,152
+33,835
+0.9% +$9.33M 0.21% 88
2020
Q2 		$1.11B Buy
3,840,317
+30,946
+0.8% +$8.39M 0.24% 76
2020
Q1 		$905M Buy
3,809,371
+237,183
+7% +$54.4M 0.24% 82
2019
Q4 		$780M Buy
3,572,188
+115,110
+3% +$23.3M 0.16% 122
2019
Q3 		$585M Buy
3,457,078
+108,297
+3% +$19.2M 0.14% 149
2019
Q2 		$613M Buy
3,348,781
+113,284
+4% +$19.8M 0.15% 129
2019
Q1 		$594M Buy
3,235,497
+176,191
+6% +$32.5M 0.15% 124
2018
Q4 		$506M Buy
3,059,306
+207,934
+7% +$36M 0.16% 121
2018
Q3 		$548M Buy
2,851,372
+69,858
+3% +$12.4M 0.15% 124
2018
Q2 		$472M Buy
2,781,514
+48,459
+2% +$7.51M 0.15% 136
2018
Q1 		$444M Buy
2,733,055
+125,804
+5% +$20.5M 0.14% 139
2017
Q4 		$390M Buy
2,607,251
+105,683
+4% +$15.6M 0.13% 147
2017
Q3 		$380M Buy
2,501,568
+114,200
+5% +$17.2M 0.14% 137
2017
Q2 		$307M Buy
2,387,368
+47,547
+2% +$5.72M 0.12% 172
2017
Q1 		$255M Buy
2,339,821
+191,154
+9% +$16.8M 0.1% 196
2016
Q4 		$158M Buy
2,148,667
+102,298
+5% +$8.32M 0.07% 269
2016
Q3 		$178M Buy
2,046,369
+58,820
+3% +$5.56M 0.09% 230
2016
Q2 		$171M Buy
1,987,549
+1,362
+0.1% +$118K 0.09% 224
2016
Q1 		$158K Buy
1,986,187
+40,848
+2% +$3.69M 0.08% 237
2015
Q4 		$244M Buy
1,945,339
+28,873
+2% +$3.49M 0.14% 141
2015
Q3 		$199M Buy
1,916,466
+15,534
+0.8% +$2M 0.12% 170
2015
Q2 		$234M Sell
1,900,932
-21,862
-1% -$2.75M 0.13% 148
2015
Q1 		$226M Buy
1,922,794
+89,425
+5% +$10.7M 0.13% 162
2014
Q4 		$218M Buy
1,833,369
+88,144
+5% +$9.93M 0.13% 159
2014
Q3 		$196M Buy
1,745,225
+4,930
+0.3% +$469K 0.13% 157
2014
Q2 		$165M Sell
1,740,295
-1,670
-0.1% -$117K 0.11% 192
2014
Q1 		$123M Buy
1,741,965
+28,146
+2% +$2.23M 0.08% 243
2013
Q4 		$127M Buy
1,713,819
+66,692
+4% +$4.64M 0.09% 228
2013
Q3 		$125M Buy
1,647,127
+740,697
+82% +$58.9M 0.1% 208
2013
Q2 		$72.4M Buy
+906,430
New +$66.8M 0.06% 310

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Geode Capital Management's VRTX Position: Q1 2026 in Review

Geode Capital Management increased its Vertex Pharmaceuticals (VRTX) stake by 2.6% in Q1 2026, buying an estimated $73.5M and bringing the position to 6,139,621 shares worth $2.73B. The position accounts for 0.17% of the portfolio, ranked #95.

Geode Capital Management first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.96B in Q2 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Geode Capital Management held 6,139,621 shares of Vertex Pharmaceuticals worth $2.73B as of Q1 2026.
  • Geode Capital Management bought 157,716 Vertex Pharmaceuticals shares in Q1 2026, an estimated $73.5M.
  • Vertex Pharmaceuticals made up 0.17% of Geode Capital Management's portfolio in Q1 2026, its #95 holding.
  • Geode Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Geode Capital Management's Vertex Pharmaceuticals position peaked at $2.96B in Q2 2024.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.